Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential

Group 1 - Olema Pharmaceuticals Inc. is recognized as a promising investment opportunity, particularly in the biotech sector for selective estrogen receptor degrader/SERD breast cancer drugs [1][3] - Guggenheim has initiated coverage of Olema with a Buy rating and a price target of $20, highlighting the potential of its lead product candidate, palazestrant, in a $10 billion market [1][3] - The company is advancing its pivotal OPERA-01 and OPERA-02 Phase 3 trials, with a selected dose of 90 mg once-daily for palazestrant [2] Group 2 - In Q2 2025, Olema reported a net loss of $43.8 million, an increase from a net loss of $30.4 million in Q2 2024, attributed to higher R&D spending for late-stage trials [3]